The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes
Abstract
Mealtime amylin replacement with the human amylin analog pramlintide as an adjunct to insulin therapy improves postprandial glycemia and long-term glycemic control in type 1 diabetes. Preclinical animal studies indicate that these complementary effects may result from at least 2 independent mechanisms: a slowing of nutrient delivery to the small intestine and a suppression of nutrient-stimulated glucagon secretion. The former effect of pramlintide has previously been demonstrated in patients with type 1 diabetes. The present studies characterize the effect of pramlintide on postprandial glucagon secretion in this patient population. Plasma glucagon and glucose concentrations were measured before and after a standardized liquid meal in 2 separate randomized, double-blind, placebo-controlled studies of pramlintide administration to patients with type 1 diabetes. In a 2-day crossover study, 18 patients received a 5-hour intravenous infusion of pramlintide (25 microg/h or 50 microg/h) or placebo in addition to subcutaneous (SC) insulin injections. In a 14-day parallel-group study, 84 patients received SC injections of 30, 100, or 300 microg of pramlintide or placebo 3 times daily in addition to SC injections of insulin. In both studies plasma glucagon concentrations increased in response to the meal in the placebo-plus-insulin group but not in any of the pramlintide-treated groups (all pramlintide treatment arms v placebo, P <.05). We conclude that mealtime amylin replacement wit…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Injection of pramlintide prior to meals acts to suppress glucagon secretion, delay gastric emptying, and promote satiety.
“Injection prior to meals acts to suppress glucagon secretion, delay gastric emptying, and promote satiety (247-250).”
Cites
Still being checked.
Cited by
Sorted by citations
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699 · see citing works
Amylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400 · see citing works
Holt, R., DeVries, J., Hess-Fischl, A., Hirsch, I., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05568-3 · Cited by 1,374 · see citing works
Ratner, R. E., Dickey, R., Fineman, M., Maggs, D. G., Shen, L., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01319.x · Cited by 307 · see citing works
Self-citationAmylin Agonists: A Novel Approach in the Treatment of Diabetes
Schmitz, O., Brock, B., & Rungby, J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s233 · Cited by 237 · see citing works
Guideline for management of postmeal glucose
Ceriello, A., Colagiuri, S., Gerich, J. E., & Tuomilehto, J. O. (2008) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.01.012 · Cited by 208 · see citing works
Levetan, C. S., Want, L. L., Weyer, C., Strobel, S. A., Crean, J., Wang, Y., Maggs, D. G., Kolterman, O., Chandran, M., Mudaliar, S. R., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.1 · Cited by 156 · see citing works
Self-citationDiabetes medications and body weight
Mitri, J., & Hamdy, O. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903081725 · Cited by 136 · see citing works
WEINZIMER, S. A., Sherr, J. L., Cengiz, E., Kim, G. E., Ruiz, J., CARRIA, L. R., Voskanyan, G. R., Roy, A., & Tamborlane, W. V. (2012) · Diabetes Care · doi:10.2337/dc12-0330 · Cited by 134 · see citing works
Kowalski, A. J. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0031 · Cited by 127 · see citing works
Weight Effect of Current and Experimental Drugs for Diabetes Mellitus
Purnell, J. Q., & Weyer, C. (2003) · Treatments in Endocrinology · doi:10.2165/00024677-200302010-00004 · Cited by 113 · see citing works
Self-citationWang, M.-Y., Yan, H., Shi, Z., Evans, M. R., Yu, X., Lee, Y., Chen, S., Williams, A., Philippe, J., Roth, M. G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424934112 · Cited by 112 · see citing works
Zhang, S., Liu, J., Dragunow, M., & Cooper, G. J. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308244200 · Cited by 111 · see citing works
Postprandial hyperglycemia and postprandial hypertriglyceridemia in type 2 diabetes
Hiyoshi, T., Fujiwara, M., & Zemin, Y. (2018) · Journal of Biomedical Research · doi:10.7555/jbr.31.20160164 · Cited by 110 · see citing works
Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1
Riddle, M. C., & Drucker, D. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1267 · Cited by 108 · see citing works
Weyer, C., Gottlieb, A., Kim, D. D. H., Lutz, K., Schwartz, S. L., Gutiérrez, M. E. H., Wang, Y., Ruggles, J. A., Kolterman, O., & Maggs, D. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3074 · Cited by 107 · see citing works
Self-citationPramlintide and the treatment of diabetes: a review of the data since its introduction
Younk, L. M., Mikeladze, M., & Davis, S. N. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.581663 · Cited by 99 · see citing works
Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes
Ryan, G., Jobe, L., & Briscoe, T. (2008) · Drug Design, Development and Therapy · doi:10.2147/dddt.s3225 · Cited by 98 · see citing works
Hoogwerf, B. J. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1978 · Cited by 87 · see citing works
Role of Amylin in Type 1 and Type 2 Diabetes
Hieronymus, L. B., & Griffin, S. (2015) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721715607642 · Cited by 86 · see citing works
Gedulin, B. R., Jodka, C. M., Herrmann, K., & Young, A. A. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.06.004 · Cited by 81 · see citing works
Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus
Singh‐Franco, D., Robles, G. I., & Gazze, D. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.04.005 · Cited by 75 · see citing works
Neuroendocrine hormone amylin in diabetes
Zhang, X., Pan, Y.-H., Huang, Y., & Zhao, H. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i9.189 · Cited by 75 · see citing works
Ceriello, A., Piconi, L., Quagliaro, L., Wang, Y., Schnabel, C. A., Ruggles, J. A., Gloster, M., Maggs, D. G., & Weyer, C. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.632 · Cited by 75 · see citing works
Self-citationBuse, J. B., Weyer, C., & Maggs, D. G. (2002) · Clinical Diabetes · doi:10.2337/diaclin.20.3.137 · Cited by 71 · see citing works
Self-citationPramlintide for the Treatment of Insulin-Requiring Diabetes Mellitus
Kruger, D. F., & Gloster, M. (2004) · Drugs · doi:10.2165/00003495-200464130-00003 · Cited by 70 · see citing works
Mediators of Amylin Action in Metabolic Control
Boyle, C. N., Zheng, Y., & Lutz, T. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082207 · Cited by 68 · see citing works
Pramlintide in the Treatment of Diabetes Mellitus
Edelman, S. V., Maier, H., & Wilhelm, K. (2008) · BioDrugs · doi:10.2165/0063030-200822060-00004 · Cited by 68 · see citing works
Effect of a glucagon receptor antibody (REMD‐477) in type 1 diabetes: A randomized controlled trial
Pettus, J., Reeds, D. N., Cavaiola, T. S., BOEDER, S. C., Levin, M., Tobin, G. S., Cava, E., Thai, D. L., Shi, J., Yan, H., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13202 · Cited by 67 · see citing works
Riddle, M., Pencek, R., Charenkavanich, S., Lutz, K., Wilhelm, K., & Porter, L. (2009) · Diabetes Care · doi:10.2337/dc09-0395 · Cited by 66 · see citing works
The Alpha-Cell as Target for Type 2 Diabetes Therapy
Christensen, M., Bagger, J. I., Vilsbøll, T., & Knop, F. K. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.369 · Cited by 65 · see citing works
Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes
Pullman, J. R., Darsow, T., & Frías, J. P. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.203 · Cited by 64 · see citing works
Amylin-mediated control of glycemia, energy balance, and cognition
Mietlicki‐Baase, E. G. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.02.034 · Cited by 62 · see citing works
Interaction of amylin species with transition metals and membranes
Alghrably, M., Czaban, I., Jaremko, Ł., & Jaremko, M. (2018) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2018.11.004 · Cited by 58 · see citing works
Lutz, T. A. (2022) · Appetite · doi:10.1016/j.appet.2022.105965 · Cited by 59 · see citing works
Yang, J., Robert, C. E., Burkhardt, B. R., Young, R. A., Wu, J., Gao, Z., & Wolf, B. A. (2005) · Diabetes · doi:10.2337/diabetes.54.11.3217 · Cited by 58 · see citing works
Adjunct therapy for type 1 diabetes mellitus
Lebovitz, H. E. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.49 · Cited by 57 · see citing works
Qiao, Y.-C., Ling, W., Pan, Y.-H., Chen, Y.-L., Zhou, D., Huang, Y.-M., Zhang, X.-X., & Zhao, H.-L. (2017) · Oncotarget · doi:10.18632/oncotarget.16008 · Cited by 54 · see citing works
Current strategies for the inhibition of hepatic glucose production in type 2 diabetes
Dale, S. E. (2009) · Frontiers in bioscience · doi:10.2741/3301 · Cited by 55 · see citing works
Mack, C. M., Smith, P. A., Athanacio, J., Xu, K., Wilson, J., Reynolds, J. M., Jodka, C. M., Lu, M. G. W., & Parkes, D. G. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01465.x · Cited by 50 · see citing works
Faradji, R. N., Froud, T., Messinger, S., Monroy, K., Pileggi, A., Mineo, D., Tharavanij, T., Mendez, A. J., Ricordi, C., & Alejandro, R. (2009) · Cell Transplantation · doi:10.3727/096368909x474456 · Cited by 49 · see citing works
Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes
Bacha, F. F., & Bartz, S. K. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12337 · Cited by 42 · see citing works
Wang, H., Abedini, A., Ruzsicska, B. P., & Raleigh, D. P. (2014) · Biochemistry · doi:10.1021/bi500592p · Cited by 41 · see citing works
Hoerger, T. J., & Ahmann, A. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.s1-b.1 · Cited by 40 · see citing works
Nonoyama, A., Laurence, J. S., Garriques, L. N., Qi, H., Le, T. T., & Middaugh, C. R. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21197 · Cited by 39 · see citing works
Asmar, M., Bache, M., Knop, F. K., Madsbad, S., & Holst, J. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2133 · Cited by 39 · see citing works
The Role of Prandial Pramlintide in the Treatment of Adolescents With Type 1 Diabetes
Rodríguez, L. M., Mason, K. J., Haymond, M. W., & Heptulla, R. A. (2007) · Pediatric Research · doi:10.1203/pdr.0b013e318159af8c · Cited by 38 · see citing works
Karl, D. M., Philis‐Tsimikas, A., Darsow, T., Lorenzi, G. M., Kellmeyer, T., Lutz, K., Wang, Y., & Frías, J. P. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.0013 · Cited by 38 · see citing works
Human Amylin: From Pathology to Physiology and Pharmacology
Ling, W., Huang, Y., Qiao, Y.-C., Zhang, X., & Zhao, H. (2019) · Current Protein and Peptide Science · doi:10.2174/1389203720666190328111833 · Cited by 37 · see citing works
Novel insights into the pathogenic impact of diabetes on the gastrointestinal tract
Portincasa, P., Bonfrate, L., Wang, D. Q., Frühbeck, G., Garruti, G., & Ciaula, A. D. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13846 · Cited by 37 · see citing works
Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes
Maggs, D. G., Macdonald, I. A., & Nauck, M. A. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00737.x · Cited by 34 · see citing works
Self-citationManipulation of Post-Prandial Hyperglycaemia in Type 2 Diabetes: An Update for Practitioners
Shibib, L., Al-Qaisi, M., Guess, N. D., Miras, A. D., Greenwald, S. E., Pelling, M., & Ahmed, A. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s458894 · Cited by 39 · see citing works
Grunberger, G. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12034 · Cited by 32 · see citing works
Wysham, C., Lush, C. W., Zhang, B., Maier, H., & Wilhelm, K. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x253537 · Cited by 32 · see citing works
Copper(II) and Amylin Analogues: A Complicated Relationship
Alghrably, M., Dudek, D., Emwas, A.-H. M., Jaremko, Ł., Jaremko, M., & Rowińska‐Żyrek, M. (2020) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.9b03498 · Cited by 31 · see citing works
Heise, T., Heinemann, L., Heller, S. R., Weyer, C., Wang, Y., Strobel, S. A., Kolterman, O., & Maggs, D. G. (2004) · Metabolism · doi:10.1016/j.metabol.2004.04.010 · Cited by 29 · see citing works
Self-citationAmylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity
Volčanšek, Š., Koceva, A., Jensterle, M., Janež, A., & Muzurović, E. M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01733-8 · Cited by 26 · see citing works
Amiel, S. A., Heller, S. R., Macdonald, I. A., Schwartz, S. L., Klaff, L. J., Ruggles, J. A., Weyer, C., Kolterman, O., & Maggs, D. G. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00417.x · Cited by 25 · see citing works
Self-citationAkter, R., Bower, R. L., Abedini, A., Schmidt, A. M., Hay, D. L., & Raleigh, D. P. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00690 · Cited by 23 · see citing works
New physiological effects of the incretin hormones GLP-1 and GIP.
Asmar, M. (2011) · PubMed · Cited by 21 · see citing works
Jeha, G. S., & Heptulla, R. A. (2006) · Pediatric Diabetes · doi:10.1111/j.1399-543x.2006.00159.x · Cited by 22 · see citing works
A Pilot Trial of Pramlintide Home Usage in Adolescents With Type 1 Diabetes
Kishiyama, C. M., Burdick, P., Cobry, E. C., Gage, V., Messer, L. H., McFann, K., & Chase, H. P. (2009) · PEDIATRICS · doi:10.1542/peds.2008-3750 · Cited by 21 · see citing works
Pharmacotherapy for Obese Adolescents
Greydanus, D. E., Bricker, L. A., & Feucht, C. L. (2011) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2010.10.007 · Cited by 21 · see citing works
THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin – physiology and pharmacology
Mathiesen, D. S., Lund, A., Holst, J. J., Knop, F. K., Lutz, T. A., & Bagger, J. I. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1261 · Cited by 21 · see citing works
Beglinger, S., Meyer‐Gerspach, A. C., Graf, S., Zumsteg, U., Drewe, J., Beglinger, C., & Gutzwiller, J. (2014) · Obesity · doi:10.1002/oby.20805 · Cited by 21 · see citing works
Micheletto, F., Man, C. D., Kolterman, O., Chiquette, E., Herrmann, K., Schirra, J. R. J., Kovatchev, B. P., & Cobelli, C. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0054 · Cited by 21 · see citing works
Self-citationTreating the elderly diabetic patient: special considerations
Barski, L., Kezerle, L., & Shalev, L. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s48898 · Cited by 21 · see citing works
Hassan, K., & Heptulla, R. A. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2008.00490.x · Cited by 21 · see citing works
Adjuvantes no tratamento da hiperglicemia do diabetes melito tipo 1
Gabbay, M. A. L. (2008) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302008000200015 · Cited by 20 · see citing works
Islet amyloid toxicity: From genesis to counteracting mechanisms
Marmentini, C., Branco, R. C. S., Boschero, A. C., & Kurauti, M. A. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30600 · Cited by 19 · see citing works
Huffman, D. M., McLean, G. W., & Seagrove-Guffey, M. (2009) · Endocrine Practice · doi:10.4158/ep09044.orr1 · Cited by 19 · see citing works
Herrmann, K., Brunell, S. C., Li, Y., Zhou, M., & Maggs, D. G. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0326-5 · Cited by 18 · see citing works
Self-citationRiddle, M. C. (2020) · Diabetes Care · doi:10.2337/dci19-0077 · Cited by 18 · see citing works
Herrmann, K., Zhou, M., Wang, A., & de Bruin, T. W. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0030-z · Cited by 18 · see citing works
Peyrot, M. F., Rubin, R. R., & Polonsky, W. H. (2008) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0031 · Cited by 18 · see citing works
Pramlintide: Clinical Strategies for Success
Alrefai, H. A., Latif, K. A., Hieronymus, L. B., Weakley, C. R., & Moss, R. J. (2010) · Diabetes Spectrum · doi:10.2337/diaspect.23.2.124 · Cited by 16 · see citing works
Kellmeyer, T., Kesty, N. C., Wang, Y., Frías, J. P., & Fineman, M. S. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007300949 · Cited by 16 · see citing works
Self-citationUpdate in the Pharmacologic Treatment of Diabetes Mellitus
Odegard, P. S., Setter, S. M., & Iltz, J. L. (2006) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721706294003 · Cited by 16 · see citing works
Effects of a Patient Education Support Program on Pramlintide Adherence
Lorenzi, G. M., LaRue, S. M., & Collins, S. E. (2011) · Clinical Diabetes · doi:10.2337/diaclin.29.1.17 · Cited by 15 · see citing works
Akter, R., Abedini, A., Ridgway, Z., Zhang, X., Kleinberg, J., Schmidt, A., & Raleigh, D. (2016) · Israel Journal of Chemistry · doi:10.1002/ijch.201600081 · Cited by 13 · see citing works
Weight Management in Type 2 Diabetes Mellitus
Siram, A. T., Yanagisawa, R. T., & Skamagas, M. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20208 · Cited by 14 · see citing works
Fang, J., Landersdorfer, C. B., Cirincione, B. B., & Jusko, W. J. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9409-7 · Cited by 14 · see citing works
The latest pharmacotherapy options for type 1 diabetes
Ludvigsson, J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.855197 · Cited by 13 · see citing works
New Potential Adjuncts to Treatment of Children With Type 1 Diabetes Mellitus
Raman, V. S., & Heptulla, R. A. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e3181975ee4 · Cited by 13 · see citing works
Ruggles, J. A., Kelemen, D. W., & Baron, A. (2004) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(03)00098-7 · Cited by 13 · see citing works
Primer on Pramlintide, an Amylin Analog
Traina, A. N., & Kane, M. P. (2011) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721711403011 · Cited by 12 · see citing works
Phillips, L. K., & Horowitz, M. (2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000216969.59375.39 · Cited by 12 · see citing works
Sah, S. K., Samuel, V. P., Dahiya, S., Singh, Y., Gilhotra, R. M., Gupta, G., Mishra, A., Sharma, R. K., Kumar, G. S., Sreeharsha, N., et al. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.04.022 · Cited by 11 · see citing works
Amylin in vasodilation, energy expenditure and inflammation
Yang, F. (2014) · Frontiers in bioscience · doi:10.2741/4258 · Cited by 10 · see citing works
Role of amylin in feeding and satiation
Lutz, T. A. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110587 · Cited by 9 · see citing works
Physiological and Pathophysiological Control of Glucagon Secretion by Pancreatic α-Cells
Gilon, P., Cheng, R., Lai, B. K., Chae, H., & Gómez-Ruiz, A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_37-2 · Cited by 8 · see citing works
Nutrient synchrony in preruminant calves
van den Borne, J. J. G. C. (2006) · doi:10.18174/19267 · Cited by 8 · see citing works
King, A. B. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0096 · Cited by 7 · see citing works
Jordi, J., Herzog, B., Lutz, T. A., & Verrey, F. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00273.2014 · Cited by 7 · see citing works
HORMONE BASED THERAPY IN TYPE 2 DIABETES MELLITUS
Kothandam, H., Umamaheswari, P., & Wicket, S. D. (2012) · Cited by 7 · see citing works
The Physiology of Amylin and Insulin
Martin, C. (2006) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721706288s237 · Cited by 7 · see citing works
Understanding Amylin Receptors
Just, R., Simms, J., Furness, S. G. B., Christopoulos, A., & Sexton, P. M. (2009) · Springer eBooks · doi:10.1007/978-90-481-2909-6_3 · Cited by 7 · see citing works
Physiological models for artificial pancreas development
VISENTIN, R., Schiavon, M., Basu, R., Basu, A., Man, C. D., & Cobelli, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815655-1.00015-6 · Cited by 7 · see citing works
Pramlintide acetate in the treatment of Type 2 and Type 1 diabetes mellitus
Edelman, S. V., Schroeder, B. E., & Frías, J. P. (2006) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2.1.9 · Cited by 6 · see citing works
Kruger, D. F., Aronoff, S. L., & Edelman, S. V. (2007) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721707299766 · Cited by 6 · see citing works
- Authors
- Fineman, M. S., Koda, J. E., Shen, L. Z., Strobel, S. A., Maggs, D. G., Weyer, C., & Kolterman, O. G.
- Venue
- Metabolism
- Publisher
- Elsevier BV
- Published
- 2002-05
- Volume
- 51
- Issue
- 5
- Pages
- 636-641
- ISSN
- 0026-0495 (ISSN-L)
- OpenAlex
- W2055928432
- Cited by
- 129
- References
- 0
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 4 · 2021: 3 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 2 · 2016: 7 · 2015: 6 · 2014: 7 · 2013: 4 · 2012: 4
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
- Keywords
- pramlintide, amylin analogues, type 1 diabetes, glucagon secretion, insulin therapy, glycemic control
- MeSH terms
- Adolescent, Adult, Amyloid, Blood Glucose, Diabetes Mellitus, Type 1, Double-Blind Method, Fasting, Female, Food, Glucagon, Humans, Hypoglycemic Agents, Kinetics, Male, Middle Aged, Placebos, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
